Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.80 |
| ▸ | TP53 | P04637 | 3/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | HPGD | P15428 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.61 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | TYR | P14679 | 2/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082769 | 0.89 | ALOX15 (0.84) | ALOX15TP53CYP3A4LMNAHPGD | |
| SCHEMBL29381356 | 0.89 | ALOX15 (1.00) | ALOX15TP53CYP3A4LMNAHPGD | |
| SCHEMBL39215 | 0.89 | ALOX15 (1.00) | ALOX15TP53CYP3A4LMNAHPGD | |
| SCHEMBL2741238 | 0.85 | ALOX15 (0.71) | ALOX15TP53CYP3A4LMNAHPGD | |
| SCHEMBL20253183 | 0.84 | ALOX15 (0.69) | ALOX15TP53CYP3A4LMNAHPGD | |
| SCHEMBL9631376 | 0.84 | CYP3A4 (0.69) | ALOX15TP53CYP3A4LMNAHPGD | |
| SCHEMBL2946854 | 0.83 | CYP3A4 (0.60) | ALOX15TP53CYP3A4LMNAHPGD | |
| SCHEMBL18198041 | 0.82 | ALOX15 (0.79) | ALOX15TP53CYP3A4LMNAHPGD | |
| SCHEMBL158789 | 0.82 | ALOX15 (0.80) | ALOX15TP53CYP3A4LMNAHPGD | |
| SCHEMBL29433129 | 0.82 | ALOX15 (0.80) | ALOX15TP53CYP3A4LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448171-B1 | TRANSITION METAL COMPLEX HYDROFORMYLATION CATALYST PRECUROR COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND HYDROFORMYLATION PROCESSES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240399349-A1 | TRANSITION METAL COMPLEX HYDROFORMYLATION CATALYST PRECUROR COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND HYDROFORMYLATION PROCESSES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4448171-A1 | TRANSITION METAL COMPLEX HYDROFORMYLATION CATALYST PRECUROR COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND HYDROFORMYLATION PROCESSES | Dow Technology Investments LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118338965-A | Transition metal complex hydroformylation catalyst precursor compositions comprising such compounds and hydroformylation process | 陶氏技术投资有限责任公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2023114578-A1 | TRANSITION METAL COMPLEX HYDROFORMYLATION CATALYST PRECUROR COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND HYDROFORMYLATION PROCESSES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | RPS12, GPR119, ATP12A | ALOX15 467/4885TP53 4503/4885CYP3A4 1149/4885 |
| US-20240399349-A1 | TRANSITION METAL COMPLEX HYDROFORMYLATION CATALYST PRECUROR COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND HYDROFORMYLATION PROCESSES | M6PR, KRAS, C1R | ALOX15 1734/4885TP53 3095/4885CYP3A4 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.